Gilead and Teva prevail in $3.6bn antitrust trial

Gilead Sciences and Teva Pharmaceuticals Industries have received a favourable verdict in an HIV antitrust trial in the US District Court for the Northern District of California.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

US govt seeks new trial in Gilead HIV drug patent case

18 May 2023 The government lost its high stakes and unusual royalties dispute with the big pharma firm | New status report claims that the court should have allowed the jury to take four inter partes petitions into account.

Big Pharma

Gilead defeats US govt in billion-dollar HIV drug patent suit

11 May 2023 Jury finds three US government patents over PrEP to be invalid | Case thought to be the first time US government has sued a pharmaceutical firm over patents.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Barnes & Thornburg reveals five new IP leaders

Former PTAB judge joins Sterne Kessler

Gilead and Teva prevail in $3.6bn antitrust trial

More on this story

Editor's picks

Editor's picks

More features